Atika Capital Management LLC Takes $5.49 Million Position in Ascendis Pharma A/S $ASND

Key Points

• Atika Capital Management LLC has acquired a new stake in Ascendis Pharma A/S, investing approximately $5.49 million for 35,200 shares, representing about 0.06% ownership by the end of the last quarter.
• Several institutional investors significantly increased their stakes in Ascendis Pharma A/S, with T. Rowe Price Investment Management growing its holdings by 54.4% during the fourth quarter.
• Analysts have raised their price targets on Ascendis Pharma A/S, with UBS Group setting a new target at $307.00, reflecting strong confidence in the stock's performance.

Atika Capital Management LLC purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 35,200 shares of the biotechnology company's stock, valued at approximately $5,486,000. Atika Capital Management LLC owned approximately 0.06% of Ascendis Pharma A/S as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. T. Rowe Price Investment Management Inc. grew its holdings in shares of Ascendis Pharma A/S by 12.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company's stock valued at $475,970,000 after acquiring an additional 328,278 shares in the last quarter. Hsbc Holdings PLC purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at $661,000. Brooklyn Investment Group grew its holdings in shares of Ascendis Pharma A/S by 332.9% during the 1st quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 273 shares in the last quarter. Algert Global LLC purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at $397,000. Finally, American Century Companies Inc. grew its holdings in shares of Ascendis Pharma A/S by 13.5% during the 1st quarter. American Century Companies Inc. now owns 462,171 shares of the biotechnology company's stock valued at $72,034,000 after acquiring an additional 54,877 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have recently commented on ASND shares. Morgan Stanley started coverage on shares of Ascendis Pharma A/S in a report on Thursday, July 3rd. They set an "overweight" rating and a $250.00 price target on the stock. Wedbush lifted their price objective on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Cowen reaffirmed a "buy" rating on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Cantor Fitzgerald lifted their price objective on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the company an "overweight" rating in a research note on Friday, August 8th. Finally, Citigroup reaffirmed a "buy" rating and issued a $290.00 price objective (up previously from $243.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Fifteen analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $243.36.

Ascendis Pharma A/S Trading Down 2.0%

Ascendis Pharma A/S stock traded down $3.93 on Monday, reaching $190.37. 353,956 shares of the stock were exchanged, compared to its average volume of 493,378. The stock has a market cap of $11.65 billion, a PE ratio of -36.89 and a beta of 0.41. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $199.99. The firm has a fifty day moving average price of $178.20 and a two-hundred day moving average price of $163.98.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping analysts' consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million for the quarter, compared to analyst estimates of $163.17 million. Equities analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.